[go: up one dir, main page]

WO2003045329A3 - Procedes de purification de levofloxacine - Google Patents

Procedes de purification de levofloxacine Download PDF

Info

Publication number
WO2003045329A3
WO2003045329A3 PCT/US2002/038182 US0238182W WO03045329A3 WO 2003045329 A3 WO2003045329 A3 WO 2003045329A3 US 0238182 W US0238182 W US 0238182W WO 03045329 A3 WO03045329 A3 WO 03045329A3
Authority
WO
WIPO (PCT)
Prior art keywords
levofloxacin
purification
methods
purified
antioxidant
Prior art date
Application number
PCT/US2002/038182
Other languages
English (en)
Other versions
WO2003045329A2 (fr
Inventor
Valerie Niddam-Hildesheim
Neomi Gershon
Eduard Schwartz
Original Assignee
Teva Pharma
Valerie Niddam-Hildesheim
Neomi Gershon
Eduard Schwartz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/263,192 external-priority patent/US7629458B2/en
Priority to KR10-2004-7008039A priority Critical patent/KR20040058336A/ko
Priority to HU0500285A priority patent/HUP0500285A3/hu
Priority to AU2002365416A priority patent/AU2002365416A1/en
Priority to MXPA04005196A priority patent/MXPA04005196A/es
Priority to JP2003546834A priority patent/JP2005527484A/ja
Application filed by Teva Pharma, Valerie Niddam-Hildesheim, Neomi Gershon, Eduard Schwartz filed Critical Teva Pharma
Priority to IL16217202A priority patent/IL162172A0/xx
Priority to EP02791339A priority patent/EP1460997A4/fr
Priority to HR20040546A priority patent/HRP20040546A2/hr
Priority to CA002466860A priority patent/CA2466860A1/fr
Publication of WO2003045329A2 publication Critical patent/WO2003045329A2/fr
Publication of WO2003045329A3 publication Critical patent/WO2003045329A3/fr
Priority to IS7288A priority patent/IS7288A/is
Priority to NO20042731A priority patent/NO20042731L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)

Abstract

Selon l'invention, la levofloxacine est purifiée par dissolution de celle-ci dans un solvant polaire à une température élevée et par cristallisation de la levofloxacine purifiée. De préférence, un antioxydant est ajouté aux fins d'augmenter sa pureté.
PCT/US2002/038182 2001-11-29 2002-11-27 Procedes de purification de levofloxacine WO2003045329A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002466860A CA2466860A1 (fr) 2001-11-29 2002-11-27 Procedes de purification de levofloxacine
EP02791339A EP1460997A4 (fr) 2001-11-29 2002-11-27 Procedes de purification de levofloxacine
AU2002365416A AU2002365416A1 (en) 2001-11-29 2002-11-27 Methods for the purification of levofloxacin
MXPA04005196A MXPA04005196A (es) 2001-11-29 2002-11-27 Metodos para la purificacion de levofloxacina.
JP2003546834A JP2005527484A (ja) 2001-11-29 2002-11-27 レボフロキサシンの精製製法
KR10-2004-7008039A KR20040058336A (ko) 2001-11-29 2002-11-27 레보플록사신의 정제 방법
IL16217202A IL162172A0 (en) 2001-11-29 2002-11-27 Methods for the purification of levofloxacin
HU0500285A HUP0500285A3 (en) 2001-11-29 2002-11-27 Methods for the purification of levofloxacin
HR20040546A HRP20040546A2 (en) 2001-11-29 2002-11-27 Methods for the purification of levofloxacin
IS7288A IS7288A (is) 2001-11-29 2004-05-27 Aðferðir til að hreinsa levófloxasín
NO20042731A NO20042731L (no) 2001-11-29 2004-06-29 Fremgangsmater for rensing av levofloxacin

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US33431601P 2001-11-29 2001-11-29
US60/334,316 2001-11-29
US35493902P 2002-02-11 2002-02-11
US60/354,939 2002-02-11
US26296502A 2002-10-03 2002-10-03
US10/263,192 2002-10-03
US10/263,192 US7629458B2 (en) 2001-10-03 2002-10-03 Preparation of levofloxacin and hemihydrate thereof
US10/262,965 2002-10-03

Publications (2)

Publication Number Publication Date
WO2003045329A2 WO2003045329A2 (fr) 2003-06-05
WO2003045329A3 true WO2003045329A3 (fr) 2004-02-19

Family

ID=31892240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038182 WO2003045329A2 (fr) 2001-11-29 2002-11-27 Procedes de purification de levofloxacine

Country Status (13)

Country Link
EP (1) EP1460997A4 (fr)
JP (3) JP2005527484A (fr)
CN (1) CN1596256A (fr)
AU (1) AU2002365416A1 (fr)
CA (1) CA2466860A1 (fr)
HR (1) HRP20040546A2 (fr)
HU (1) HUP0500285A3 (fr)
IL (1) IL162172A0 (fr)
IS (1) IS7288A (fr)
MX (1) MXPA04005196A (fr)
NO (1) NO20042731L (fr)
PL (1) PL374558A1 (fr)
WO (1) WO2003045329A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1451194E (pt) 2001-10-03 2007-01-31 Teva Pharma Preparação de hemi-hidrato de levofloxacina
US20060276463A1 (en) * 2002-12-16 2006-12-07 Sharma Tarun K Pure levofloxacin hemihydrate and processes for preparation thereof
KR100704641B1 (ko) * 2004-07-21 2007-04-06 주식회사유한양행 고순도의 레보플록사신 제조방법
JP2006273718A (ja) * 2005-03-28 2006-10-12 Shiono Chemical Co Ltd レボフロキサシン・１／２水和物の製法
CN1321121C (zh) * 2005-04-21 2007-06-13 浙江医药股份有限公司新昌制药厂 左氧氟沙星制备及后处理方法
US7964723B2 (en) * 2008-08-02 2011-06-21 Apeloa-Kangyu And practical process for exclusively producing (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido-[1,2,3,de][1,4]benzoxazine-6-carboxylic acid hemihydrate
CN102070650B (zh) * 2011-01-28 2012-06-27 山东省药品检验所 左氧氟沙星-n-氧化物的制备方法
US20120251685A1 (en) * 2011-04-04 2012-10-04 Martek Biosciences Corporation Oil-in-Water Emulsions Comprising a Polyunsaturated Fatty Acid and Methods of Making the Same
CN105823851A (zh) * 2015-12-15 2016-08-03 浙江海洋学院 一种检测海水中氧氟沙星对映体的方法
CN108218892A (zh) * 2018-03-16 2018-06-29 乐山职业技术学院 一种左氧氟沙星的纯化方法
CN112174981A (zh) * 2020-11-03 2021-01-05 深圳市祥根生物科技有限公司 一种左氧氟沙星脱氟杂质的制备方法
CN114507242B (zh) * 2022-01-26 2023-05-19 上虞京新药业有限公司 高光学纯度左氧氟沙星的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142046A (en) * 1985-06-20 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Optically active pyridobenzoxazine derivatives and intermediates thereof
US5237060A (en) * 1985-12-10 1993-08-17 Bayer Aktiengesellschaft Process of preparing enantiomerically pure 1,8-bridged 4-quinolone-3-carboxylic acids
US5521310A (en) * 1992-10-07 1996-05-28 Derivados Del Etilo, S.A. Process to obtain benzoxazines to be used for the synthesis of ofloxazine, levofloxazine and derivatives
US5539110A (en) * 1994-03-22 1996-07-23 Korea Institute Of Science And Technology Method for the preparation of (-)piperazine benzoxazine derivatives
US5545737A (en) * 1990-03-01 1996-08-13 Daiichi Pharmaceutical Co., Ltd. Process for selectively producing an (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido (1,2,3, -de) (1,4) benzoxazine-6-carboxylic acid hemihydrate or monohydrate
US6316618B1 (en) * 1998-02-24 2001-11-13 Samsung Electronics Co., Ltd. Process for preparing (-)pyridobenzoxazine carboxylic acid derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1451194E (pt) * 2001-10-03 2007-01-31 Teva Pharma Preparação de hemi-hidrato de levofloxacina

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142046A (en) * 1985-06-20 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Optically active pyridobenzoxazine derivatives and intermediates thereof
US5237060A (en) * 1985-12-10 1993-08-17 Bayer Aktiengesellschaft Process of preparing enantiomerically pure 1,8-bridged 4-quinolone-3-carboxylic acids
US5545737A (en) * 1990-03-01 1996-08-13 Daiichi Pharmaceutical Co., Ltd. Process for selectively producing an (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido (1,2,3, -de) (1,4) benzoxazine-6-carboxylic acid hemihydrate or monohydrate
US5521310A (en) * 1992-10-07 1996-05-28 Derivados Del Etilo, S.A. Process to obtain benzoxazines to be used for the synthesis of ofloxazine, levofloxazine and derivatives
US5539110A (en) * 1994-03-22 1996-07-23 Korea Institute Of Science And Technology Method for the preparation of (-)piperazine benzoxazine derivatives
US6316618B1 (en) * 1998-02-24 2001-11-13 Samsung Electronics Co., Ltd. Process for preparing (-)pyridobenzoxazine carboxylic acid derivatives

Also Published As

Publication number Publication date
CN1596256A (zh) 2005-03-16
CA2466860A1 (fr) 2003-06-05
JP2006219496A (ja) 2006-08-24
IL162172A0 (en) 2005-11-20
EP1460997A4 (fr) 2005-06-15
MXPA04005196A (es) 2005-11-23
WO2003045329A2 (fr) 2003-06-05
HRP20040546A2 (en) 2004-10-31
HUP0500285A2 (hu) 2005-06-28
IS7288A (is) 2004-06-21
JP2008007517A (ja) 2008-01-17
NO20042731L (no) 2004-06-29
PL374558A1 (en) 2005-10-31
HUP0500285A3 (en) 2009-03-30
JP2005527484A (ja) 2005-09-15
AU2002365416A1 (en) 2003-06-10
EP1460997A2 (fr) 2004-09-29

Similar Documents

Publication Publication Date Title
WO2003028665A3 (fr) Techniques de purification de la lévofloxacine
WO2003045329A3 (fr) Procedes de purification de levofloxacine
DK1518859T3 (da) Fremgangsmåde til oprensning af thiophener
RS86804A (en) Quinoline and isoquinoline derivatives method for the production thereof and use therof as anti-inflammatory agents
AU2003282094A1 (en) Novel dihydroxy-methylphenyl derivatives, method for the production and use thereof as medicaments
IL162461A0 (en) Polymorphs of clopidogrel hydrogensulfate
AU2001217248A1 (en) Process for the recovery of crude terephthalic acid (cta)
CA2359810A1 (fr) Procede de preparation de citalopram pur
WO2004035800A3 (fr) Sels d'intermediaire de cefdinir
AU2003301508A1 (en) Processes for producing glutamic acid derivative and pyroglutamic acid derivative and novel intermediate for production
MXPA03011954A (es) Nuevos derivados de acido sulfonico.
AU2003282383A1 (en) A process for the preparation of high purity escitalopram
WO2004050663A3 (fr) Procede ameliore de preparation de cefuroxime sodique
MY141020A (en) Novel pparalpha and ppargamma agonists
WO2002092602A3 (fr) Procedes de synthese de derives de 2,3-dihydro-1,4-dioxino-[2,3-f] quinoline
WO2003011228A3 (fr) Procede de purification de n-[3-(3-cyanopyrazolo[1,5-a]pyrimidine-7-yl)phenyl]-n-ethylacetamide(zaleplon) et des formes cristallines de zaleplon auxquelles ce procede donne acces
WO2004050616A3 (fr) Traitement du syndrome du colon irritable et de la dyspepsie non ulcereuse au moyen de 2,3-benzodiazepines substituees
TW200517368A (en) Process
WO2003029254A1 (fr) Procede de preparation de composes tricycliques
WO2000071551A3 (fr) Purification d'un compose organometallique
EP2070931A3 (fr) Procédé pour la préparation de 2-fluoroadénine
HK1039932A1 (zh) 使用馬杜拉二氮雜萘衍生物抑制前炎性細胞質變化
WO2004010931A3 (fr) Compositions de tocopherol de couleur stable et comportant peu d'impuretes, et procedes de preparation de ceux-ci
WO2002094773A3 (fr) Procede d'isolation de l'imipeneme cristallin
AU2003219423A1 (en) Process for the isolation of high purity crystalline citalopram base

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2466860

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004/03672

Country of ref document: ZA

Ref document number: 200403672

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1320/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002365416

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 162172

Country of ref document: IL

Ref document number: 1020047008039

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 374558

Country of ref document: PL

Ref document number: PA/a/2004/005196

Country of ref document: MX

Ref document number: 20028236440

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003546834

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: P20040546A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2002791339

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 533768

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2002791339

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 196881

Country of ref document: IL